In addition, it was revealed that Kyn treatment promoted U87MG cell migration and invasion (Fig. 4g), and the decrease in glioma cell motility caused by IDO1 inhibition or TDO knockdown was restored when exogenous Kyn was supplemented (Fig. 4h, i). The gene discussed is TDO2; the disease is central nervous system cancer.